Rimeporide - EspeRare Foundation

Drug Profile

Rimeporide - EspeRare Foundation

Alternative Names: EMD 87580

Latest Information Update: 13 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono
  • Developer Childrens National Health System; EspeRare Foundation; Merck Serono; University of Geneva
  • Class Anti-inflammatories; Antifibrotics; Benzamides; Heart failure therapies; Small molecules; Sulfones
  • Mechanism of Action Sodium hydrogen antiporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Duchenne muscular dystrophy
  • Discontinued Heart failure

Most Recent Events

  • 16 Mar 2018 EspeRare plans a phase II/III trial for Neuromuscular disorders and Cardiomyopathies by the end of 2018/early 2019
  • 01 Feb 2018 EspeRare completes phase-I clinical trials in Duchenne muscular dystrophy (In adolescents, In children) in Spain, France, Italy and United Kingdom (PO) (EudraCT2015-002530-50)
  • 01 Aug 2017 EspeRare Foundation expects to launch rimeporide by 2020-2021 (EspeRare website, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top